[go: up one dir, main page]

DK2204174T3 - Fremgangsmåde til opløseliggørelsen af metronidazol ved hjælp af niacinamid og to glycoler, og den således opnåede opløsning - Google Patents

Fremgangsmåde til opløseliggørelsen af metronidazol ved hjælp af niacinamid og to glycoler, og den således opnåede opløsning

Info

Publication number
DK2204174T3
DK2204174T3 DK10160846.1T DK10160846T DK2204174T3 DK 2204174 T3 DK2204174 T3 DK 2204174T3 DK 10160846 T DK10160846 T DK 10160846T DK 2204174 T3 DK2204174 T3 DK 2204174T3
Authority
DK
Denmark
Prior art keywords
metronidazole
solution
niacinamide
glycolic
solubilization
Prior art date
Application number
DK10160846.1T
Other languages
English (en)
Inventor
Claire Mallard
Alain Brzokewicz
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35597783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2204174(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Galderma Sa filed Critical Galderma Sa
Application granted granted Critical
Publication of DK2204174T3 publication Critical patent/DK2204174T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
DK10160846.1T 2005-06-17 2006-06-16 Fremgangsmåde til opløseliggørelsen af metronidazol ved hjælp af niacinamid og to glycoler, og den således opnåede opløsning DK2204174T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0506182A FR2887149B1 (fr) 2005-06-17 2005-06-17 Procede de solubilisation du metronidazole
EP06778604A EP1896016B1 (fr) 2005-06-17 2006-06-16 Procede de solubilisation du metronidazole

Publications (1)

Publication Number Publication Date
DK2204174T3 true DK2204174T3 (da) 2012-08-27

Family

ID=35597783

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10160846.1T DK2204174T3 (da) 2005-06-17 2006-06-16 Fremgangsmåde til opløseliggørelsen af metronidazol ved hjælp af niacinamid og to glycoler, og den således opnåede opløsning
DK06778604.6T DK1896016T3 (da) 2005-06-17 2006-06-16 Fremgangsmåde til solubilisering af metronidazol

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK06778604.6T DK1896016T3 (da) 2005-06-17 2006-06-16 Fremgangsmåde til solubilisering af metronidazol

Country Status (13)

Country Link
US (3) US7981916B2 (da)
EP (2) EP1896016B1 (da)
AT (1) ATE476976T1 (da)
CA (1) CA2611883A1 (da)
CY (2) CY1110807T1 (da)
DE (1) DE602006016122D1 (da)
DK (2) DK2204174T3 (da)
ES (2) ES2350368T3 (da)
FR (1) FR2887149B1 (da)
PL (2) PL2204174T3 (da)
PT (2) PT1896016E (da)
SI (2) SI2204174T1 (da)
WO (1) WO2006134279A2 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
GB0615016D0 (en) * 2006-07-28 2006-09-06 Flen Pharma N V Use of polyethylene glycol in inflammation related topical disorders or diseases and wound healing
WO2010047831A1 (en) * 2008-10-23 2010-04-29 Nycomed Us Inc. Stable metronidazole gel formulations
CA3054236A1 (en) * 2011-06-28 2013-01-03 Chemo Research Sl High dosage mucoadhesive metronidazole aqueous-based gel formulations and their use to treat bacterial vaginosis
CN110996908A (zh) 2017-08-11 2020-04-10 株式会社爱茉莉太平洋 包含(r)-n-[1-(3,5-二氟-4-甲磺酰氨基-苯基)-乙基]-3-(2-丙基-6-三氟甲基-吡啶-3-基)-丙烯酰胺的药物组合物
CN115957213A (zh) * 2022-12-30 2023-04-14 青岛市胶州中心医院 一种抗感染甲硝唑制剂及其制备方法
CN118743678A (zh) * 2024-06-07 2024-10-08 中国药科大学 一种甲硝唑药物乳剂组合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032645A (en) * 1975-06-19 1977-06-28 G. D. Searle & Co. Injectable metronidazole composition
JPS5859913A (ja) * 1981-10-06 1983-04-09 Wakoudou Kk ジアゼパム注腸液
US4837378A (en) 1986-01-15 1989-06-06 Curatek Pharmaceuticals, Inc. Topical metronidazole formulations and therapeutic uses thereof
US5536743A (en) 1988-01-15 1996-07-16 Curatek Pharmaceuticals Limited Partnership Intravaginal treatment of vaginal infections with buffered metronidazole compositions
FR2722098B1 (fr) 1994-07-06 1996-08-23 Cird Galderma Nouveaux medicaments a base de metro-nidazole ou d'un melange synergetique de metronidazole et de clindamycine
US6444647B1 (en) * 1999-04-19 2002-09-03 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
IN2000KO00299A (da) * 1999-05-28 2005-11-18 Johnson & Johnson Consumer
US6468989B1 (en) * 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) * 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
WO2002094179A2 (en) * 2001-05-23 2002-11-28 J.B. Chemicals & Pharmaceuticals Ltd. Novel topical microbicidal compositions
US6881726B2 (en) * 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
KR100773537B1 (ko) * 2003-06-03 2007-11-07 삼성전자주식회사 한 개의 스위칭 소자와 한 개의 저항체를 포함하는비휘발성 메모리 장치 및 그 제조 방법
FR2887149B1 (fr) * 2005-06-17 2007-08-03 Galderma Sa Procede de solubilisation du metronidazole
KR100626381B1 (ko) * 2004-07-19 2006-09-20 삼성전자주식회사 상변화 기억 소자 및 그 형성 방법

Also Published As

Publication number Publication date
ATE476976T1 (de) 2010-08-15
PL2204174T3 (pl) 2012-10-31
PT2204174E (pt) 2012-08-09
FR2887149B1 (fr) 2007-08-03
EP2204174A1 (fr) 2010-07-07
ES2388236T3 (es) 2012-10-11
SI2204174T1 (sl) 2012-10-30
DK1896016T3 (da) 2010-11-22
US20110217357A1 (en) 2011-09-08
CA2611883A1 (fr) 2006-12-21
WO2006134279A2 (fr) 2006-12-21
CY1113401T1 (el) 2016-06-22
US7981916B2 (en) 2011-07-19
PT1896016E (pt) 2010-11-04
EP1896016A2 (fr) 2008-03-12
US20080161375A1 (en) 2008-07-03
SI1896016T1 (sl) 2010-10-29
EP2204174B1 (fr) 2012-05-16
EP1896016B1 (fr) 2010-08-11
DE602006016122D1 (de) 2010-09-23
PL1896016T3 (pl) 2011-05-31
US20100048645A1 (en) 2010-02-25
WO2006134279A3 (fr) 2007-02-22
CY1110807T1 (el) 2015-06-10
US8859603B2 (en) 2014-10-14
ES2350368T3 (es) 2011-01-21
FR2887149A1 (fr) 2006-12-22

Similar Documents

Publication Publication Date Title
CY1110807T1 (el) Μεθοδος διαλυτοποιησης μετρονιδαζολης
FR2894136B1 (fr) Article cosmetique soluble moussant
NO20080505L (no) Ionisk vaeske rekonstituerte cellulosekompositter som faste baerematriser
NO20080622L (no) Disykloalkylurea-glukokinase aktivatorer
DK1940786T3 (da) Biphenylderivater og deres anvendelse ved behandling af hepatitis C
NO20073065L (no) Injiserbare nanopartikulaere olanzapinformuleringer
WO2007003962A3 (en) Gpcr agonists
WO2007003961A3 (en) Gpcr agonists
CL2009001993A1 (es) Compuestos derivados de 6-oxo-4-fenilamino-1,6-dihidropiridina-3-amida, inhibidores de mek; proceso de preparacion de estos, utiles en el tratamiento de un trastorno hiperproliferativo o una condicion inflamatoria. (divisional de la solicitud cl 1168-06)
NO20083143L (no) Fremgangsmate og arrangement for innmating av kjemikalier i en prosesstrom
NO20085004L (no) Radioaktivt merkede dihydrotetrabenazinderivater og deres anvendelse som avbildningsmidler
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
NO20091563L (no) Proteaseresistente insulinanaloger
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
EA201170524A1 (ru) Урацилсодержащие соединения и гербициды, включающие такие соединения
ATE557023T1 (de) Piperidinylverbindungen als gpcr-agonisten
EA200901109A1 (ru) Применение n-фениламидинов в качестве гербицидов
WO2007078815A3 (en) Certain chemical entities, compositions, and methods
NO20081905L (no) Benzotiazolcyklobutylaminderivater og deres anvendelse som histamin-3-reseptorligander
CY1112980T1 (el) Φαρμακευτικες συνθεσεις, οι οποιες διαθετουν βελτιωμενα προφιλ διαλυσης για δυσδιαλυτες δραστικες ουσιες
WO2007089336A3 (en) Certain chemical entities, compositions and methods
WO2007070683A3 (en) Certain chemical entities, compositions and methods
CY1116189T1 (el) Σταθερη υγρη φαρμακευτικη συνθεση με βαση την τραζοδονη
ATE517126T1 (de) Therapeutikum für rheumatoide arthritis
WO2007070626A3 (en) Certain chemical entities, compositions and methods